Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS (NCT06846606)
A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- City of Hope National Medical Center — Duarte, California
- H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Ohio State University, The James Comprehensive Cancer — Columbus, Ohio
- UPENN Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Sarah Cannon Center for Blood Cancer at TriStar Centennia — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Relapsed Acute Myeloid Leukemia (AML) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.